PDCD1 and neoplasm: Recent reports have demonstrated that a combination of anti-PD-1/PD-L1 along with complementary checkpoint inhibitors with fractionated doses of RT and HT at 42 °C have shown a promising capability to mount an anti-tumor response to destroy PC cells more efficiently [73] (Figure 2).